TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Medivir AB ( (SE:MVIR) ) has provided an announcement.
Medivir AB announced that its selective cathepsin K inhibitor, MIV-711, has been granted Orphan Drug Designation by the FDA for the treatment of Osteogenesis Imperfecta (OI), a rare genetic disorder affecting bone fragility. This designation provides Medivir with development assistance, tax credits, and marketing exclusivity, potentially enhancing its market position. MIV-711 has shown promising results in animal models and clinical data, indicating its potential to address the unmet medical needs in OI by improving bone strength and quality.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a pharmaceutical company focused on developing innovative treatments for cancer, particularly in areas with high unmet medical needs. The company targets indication areas with limited or no available therapies, aiming to provide significant improvements for patients. Medivir is also involved in collaborations and partnerships as part of its business model, and its shares are listed on Nasdaq Stockholm’s Small Cap list.
Average Trading Volume: 737,780
Technical Sentiment Signal: Sell
Current Market Cap: SEK50.47M
Find detailed analytics on MVIR stock on TipRanks’ Stock Analysis page.